Search Results - technology+classifications+%3e+therapeutic+modalities+%3e+antibodies

31 Results

Sort By:

Value PropositionFirst-in-Class Targeting of a Novel Oncogenic Ion Channel: Inhibiting KCNK9 represents a new therapeutic modality in cancers where traditional approachesTumor-Specific Overexpression Enables Selectivity: KCNK9 is overexpressed in various tumors (e.g., breast, gastric, lung) but has limited expression in most normal tissuesPro-Apoptotic...

Published: 9/12/2025 | Inventor(s): John Laterra, Amy Fulton

Keywords(s):

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology > Breast Cancer, Clinical and Disease Specializations > Oncology > Lung Cancer, Clinical and Disease Specializations > Oncology > Gastric Cancer, Technology Classifications > Therapeutic Modalities > Antibodies

Novel monoclonal antibody inhibitors targeting potassium channel KCNK9

Unmet Need:KCNK9 is one of 15 mammalian subtypes in the highly conserved family of two-pore domain potassium channels (K2P). Under physiological conditions, KCNK9 is primarily expressed in the brain where it serves to maintain cellular membrane potentials. However, overexpression of KCNK9 has been detected in breast, lung, skin, and other cancers, and...

Published: 9/11/2025 | Inventor(s): John Laterra, Han Sun, Min Li, Amy Fulton

Keywords(s): Antibodies, Biologics, Breast Cancer, Cancers, Disease Indication, Lung Cancer, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Respiratory Diseases, Clinical and Disease Specializations > Women's Health, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Biologics, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Oncology > Breast Cancer, Clinical and Disease Specializations > Oncology > Lung Cancer

A Novel and Unique Set of Human Antibodies to Human Resistin and to Human Resitin-like Molecule Beta (RELMB) that can be used to Target these Proteins in Human Disease

Unmet NeedAutoinflammatory responses, your body’s innate defense mechanism against infections and stressors, can become overactive and cause chronic inflammation in various tissues and organs. Inflammatory diseases affect more than 200 million people worldwide and include pulmonary hypertension, scleroderma, rheumatoid arthritis, pulmonary fibrosis,...

Published: 9/11/2025 | Inventor(s): Roger Johns

Keywords(s): Antibodies, Biologics, Cardiovascular Diseases, Disease Indication, Hypertension, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Biologics, Clinical and Disease Specializations > Cardiovascular, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Cardiovascular > Hypertension

Compositions and Methods for Treating Diseases and Conditions Associated with Activation of the NLRP3 Inflammasome

Published: 9/12/2025 | Inventor(s): Roger Johns

Keywords(s):

Sustained release formulations for fat reduction

JHU Ref #: C18159Value Proposition· Sustained release of small molecule that depletes white fat· Local injectable administration with less intense dosing regimenUnmet Need· Excessive white fat accumulation, commonly associated with obesity, is a significant health concern that impacts metabolic, cardiovascular, and endocrine systems....

Published: 9/12/2025 | Inventor(s): Laura Ensign, Yub Raj Neupane, Fatemeh Rajaii

Keywords(s):

Category(s): Clinical and Disease Specializations > Endocrinology > Thyroid Disorders, Clinical and Disease Specializations > Metabolic Diseases > Obesity, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Small Molecules

Multispecific Antibodies that Induce Downregulation of Programmed Death-ligand 1

Unmet Need: It is estimated that in 2018 there were more than 17 million new cases of cancer worldwide (see ACS). Immune checkpoint therapies have become a powerful treatment route for a wide variety of cancer types and have increased the life expectancy for patients whose disease is refractory to all other therapies. Due to variability in patient response...

Published: 9/12/2025 | Inventor(s): Jamie Spangler, Seth Ludwig, Angela Zhu, Rakeeb Kureshi, Helen Dooley

Keywords(s):

Category(s): Technology Classifications > Therapeutic Modalities, Technology Classifications > Therapeutic Modalities > Antibodies

Antibodies associated with HIV control

Value Proposition· Target associated with viral load reduction identified from a large pool of study participants who had low level viremia· Potential to reduce disease severity in at-risk populations· Proactive approach to lower viral load in individuals who could become infected Unmet NeedHuman immunodeficiency virus (HIV) impacts millions...

Published: 9/12/2025 | Inventor(s): Susan Eshleman, Harry Larman, Kai Kammers, Oliver Laeyendecker, Wendy Grant-McAuley

Keywords(s):

Category(s): Clinical and Disease Specializations > Infectious Diseases > HIV, Clinical and Disease Specializations > Infectious Diseases > HIV/AIDS, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Therapeutic Antibodies

Recombinant anti-PAD4 antibodies as a treatment for lung fibrosis

Value PropositionSelective monoclonal antibody therapy to treat lung fibrosis.Directly targets immune cells to promote a pro-inflammatory pathway that reduces fibrosis.High serum levels are associated with less severe lung disease, decreased fibrosis, and improved survival in a subset of rheumatoid arthritis patients.Broadly applicable to other diseases...

Published: 9/12/2025 | Inventor(s): Erika Darrah, Felipe Andrade, Kristen Demoruelle, Elizabeth Redente

Keywords(s):

Category(s): Clinical and Disease Specializations > Fibrosis, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications, Technology Classifications > Therapeutic Modalities

Peptide-Based Antifouling Membrane Filtration Systems for Continuous Protein Harvesting

Unmet NeedCell and cell-derived therapies, including protein and antibodies, are being developed as a new and promising class of medicine. These kinds of therapeutics require a nuanced and precise manufacturing process, including bioreactors and filtration systems that can reliably obtain large quantities of the desired product consistently [8, 9]....

Published: 9/12/2025 | Inventor(s): Honggang Cui, Boran Sun, Michael Betenbaugh, David Stern

Keywords(s):

Category(s): Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Peptides

High Affinity Nanobodies Specific for Voltage Gated Sodium Channels

Unmet Need Globally, millions of patients are affected by diseases caused when mutations affect the normal function of voltage gated sodium channels (Nav). These mutations have been implicated in several human genetic diseases such as hypokalemic periodic paralysis, myotonia and Brugada syndrome. Myotopic Dystrophy alone affects at least 1 in 8,000...

Published: 9/12/2025 | Inventor(s): Sandra Gabelli, L. Mario Amzel, Lakshmi Srinivasan, Vanina Alzogaray, Manu Ben-Johny

Keywords(s):

Category(s): Technology Classifications > Therapeutic Modalities > Antibodies, Clinical and Disease Specializations > Genetic Diseases

1 2 3 4